Petros Pharmaceuticals
PTPI
PTPI was delisted on the 21st of May, 2025.
14 hedge funds and large institutions have $77.6K invested in Petros Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 0 closing their positions.
102% more capital invested
Capital invested by funds: $38.5K → $77.6K (+$39.1K)
56% more funds holding
Funds holding: 9 → 14 (+5)
0.11% more ownership
Funds ownership: 0.04% → 0.15% (+0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$115K |
| 2 |
HF
HRT Financial
New York
|
+$28.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$21.7K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$18.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.7K |
Top Sellers
PTPI Hedge Fund Activity: Q1 2025 in Review
14 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Petros Pharmaceuticals (PTPI) for Q1 2025, worth a combined $77.6K — up 102% from $38.5K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PTPI positions and 0 closed out — a net gain of 5 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $115K.
- 14 institutional investors held Petros Pharmaceuticals (PTPI) as of Q1 2025, up from 9 in Q4 2024.
- Funds reported $77.6K of Petros Pharmaceuticals stock for Q1 2025, up 102% quarter-over-quarter.
- 5 funds opened new Petros Pharmaceuticals positions in Q1 2025 and 0 closed out, a net change of +5 holders.
- The largest Petros Pharmaceuticals buyer in Q1 2025 was Jane Street, an estimated $115K added.
Based on aggregated 13F filings for Q1 2025.